Bayer's first-in-class factor XIa inhibitor has secured FDA approval for secondary stroke prevention, offering a new antithrombotic approach alongside antiplatelet therapy for selected high-risk adults.

Grünenthal has agreed to acquire Bayer's established oncology medicine Stivarga in a transaction worth up to €375 million.

The FDA has expanded the approved use of Kerendia to adults with chronic kidney disease associated with type 1 diabetes, introducing a new treatment option for this high-risk population.

The FDA has granted accelerated approval to Hyrnuo for first-line treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer carrying activating HER2/ERBB2 tyrosine kinase domain mutations.

The deal gives Bayer additional financial flexibility while allowing the company to retain operational control of its long-acting reversible contraceptives portfolio.

Deal strengthens Bayer’s position in retinal disease and glaucoma as long-acting ophthalmology therapies attract growing investment.